Secondary endpoints: details revised at 1 of 6 entries
MinorTrial sites expanded: 20 → 23 locationsv8
MinorSite details revised at 1 of 20 sitesv7
MinorTrial sites expanded: 10 → 20 locations
Eligibility criteria revised
v6
NotableTrial status changed: Active, Not Recruiting → Recruitingv5Show 5 more changesShow less
Primary and study completion pushed from Aug 23, 2027 to Feb 2, 2028
Enrollment reduced: 200 → 165 participants
Trial arms changed: 6 → 4
Secondary endpoints: 5 to 6
Study sites revised (10)
MinorTrial status: Recruiting to Active, Not Recruiting
Study sites: 4 to 10
v4
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 4
Start date changed from estimate of Nov 26, 2025 to Nov 20, 2025
v3
MinorStart date: Oct 31, 2025 to Nov 26, 2025v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.
The study is seeking participants who:
1. Are 18 to 64 years of age;
2. Were confirmed to have AD at least 6 months ago;
3. Do not have a suitable prescribed medicine for AD;
4. Are considered by their doctors to have moderate to severe AD.
The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.